AB Science S.A.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AB Science S.A.
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.